Novacyt S.A. Completion of q16 molecular diagnostics order (6012J)
December 06 2018 - 1:00AM
UK Regulatory
TIDMNCYT
RNS Number : 6012J
Novacyt S.A.
06 December 2018
Completion of substantial q16
molecular diagnostics order
Expands clinical diagnostic reach in
fast growing Chinese market
Paris, France and Camberley, UK - 6th December 2018 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, today announces it has received another
substantial order for Primerdesign's q16 molecular instruments from
a new customer within the fast growing Chinese market. The order
for 100 molecular diagnostic instruments has been paid in advance
and takes the number of q16 instruments sold into the Asia Pacific
region to over 230 units.
The genesig(R) q16 is Primerdesign's proprietary molecular
testing instrument which is designed to make DNA testing affordable
and easy to use. The latest order comes from a new distributor
recently appointed by Novacyt and the instruments will be used in
clinical diagnostic markets. This new customer provides Novacyt
with a potential opportunity for further significant instrument,
and genesig(R) reagent sales in 2019.
Primerdesign has now sold over 450 q16 units since its launch in
2015. As instrument sales grow, the Company expects a pull-through
effect in relation to repeat genesig(R) reagent sales. Reflecting
this, year to date genesig(R) reagent sales have increased 35%
versus the comparable period in 2017.
Graham Mullis, Group CEO of Novacyt, commented:
"I am very pleased to see this order from another new customer
in China which helps to further reinforce our continued investment
and success in the Asia Pacific region and provides additional
opportunities for future instrument and reagent sales".
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint
Broker)
Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is a rapidly growing, international
diagnostics group with a growing portfolio of cancer and infectious
disease products and services. Through its proprietary technology
platform, NOVAPrep(R), and molecular platform, genesig(R), Novacyt
is able to provide an extensive range of oncology and infectious
disease diagnostic products across an extensive international
distributor network. The Group has diversified sales from
diagnostic reagents used in oncology, microbiology, haematology and
serology markets, and its global customers and partners include
major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCZMMGZZKFGRZZ
(END) Dow Jones Newswires
December 06, 2018 02:00 ET (07:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024